globo H and related anticancer vaccines containing novel glycolipid adjuvants

A glycan and antigen technology, applied in the field of anti-cancer GloboH-DT vaccine, can solve the problem of difficulty in the precise determination of glycocomplexation

Active Publication Date: 2016-04-06
ACAD SINIC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the precise determination of this glycocomplexation is extremely difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • globo H and related anticancer vaccines containing novel glycolipid adjuvants
  • globo H and related anticancer vaccines containing novel glycolipid adjuvants
  • globo H and related anticancer vaccines containing novel glycolipid adjuvants

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0182] Example 1: Synthesis of GloboH complexed with different carrier proteins

[0183] GloboH was synthesized using a programmable one-pot strategy for process control (1; see Figure 11) and its fragment 2-10 (Huang C-Y, et al. (2006) ProcNatlAcadSciUSA103: 15-20). The reaction of 1 is carried out with sufficient homobifunctional (homobifunctional) linkers in anhydrous DMF solution at room temperature (WuX, et al. (2004) Org Lett6: 4407-4410; WuX, BundleDR (2005) JOrgChem70 :7381-7388). The reaction can be easily monitored by TLC. Once the free amine disappeared and the larger Rf product appeared, the reaction mixture was evaporated to remove DMF and washed with dichloromethane and water to remove excess linker. Finally, the product was purified by reverse-phase (C18) column chromatography and gradually eluted with water containing 1% acetic acid to 40% methanol in water. The solution was then lyophilized to yield the pale yellow product 12. Finally, for protein comple...

example 2

[0186] Example 2: Fabrication and Validation of Glycan Microarrays

[0187] Make the synthetic GloboH and cut fragment ( figure 1 ) was attached to the reducing end with a pentylamine linker and covalently immobilized on NHS-coated glass slides. Of the eleven oligosaccharides, nine were selected to be imprinted on the microarray. A series of oligosaccharide concentrations (1, 5, 10, 20, 40, 50, 80, 100 [mu]M) were tested to optimize binding affinity and fluorescence intensity. Each microarray slide was spotted with 12 replicates of nine GloboH analogs (SSEA-4, GH, Gb5, Gb4, Gb3, Gb2, BB4, BB3, and BB2) at 50 μM each. After reacting in an 80% humidity atmosphere, the slides were stored in a desiccator at room temperature until use.

[0188] To validate carbohydrates on microarrays, mouse monoclonal antibodies (VK9 and Mbr1 against GloboH, and anti-SSEA-3) and corresponding secondary antibodies (goat anti-mouse IgG and IgM) were used to test pool specificity , and the result...

example 3

[0189] Example 3: Mouse Immunization

[0190] In this experiment, a group of mice were immunized subcutaneously with 1 μg of the synthetic GloboH(GH)-complex in the presence or absence of the glycolipid adjuvant α-GalCer(C1). After 10 days of three immunizations at weekly intervals, mouse sera were collected and subsequently introduced into glycan microarrays to assess antibody levels. It is found that GH-KLH, GH-DT, and GH-BV are the most effective immunogens induced by IgM, followed by GH-TT and GH-BSA, such as Figure 3A Abstract, and α-GalCer can stimulate the immune response to induce high levels of IgM antibodies. A similar tendency was also observed for mouse IgG antibodies ( Figure 3B ), and the relative IgG content is higher than the IgM content. In brief, despite the lower sugar density of the synthetic glycoconjugate, GH-DT has similar immunogenicity to GH-KLH, and α-GalCer adjuvant was shown to enhance the immune response.

[0191] Since C1 has been shown to b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CDId on a dendritic cell, such as an a-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM 197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM 197.

Description

[0001] Cross References to Related Applications [0002] This application is a continuation-in-part of U.S. Patent Application Serial No. 12 / 485,546 (invention title "Compositions for inducing immune responses specific to Globo Hand SSEA-3 and use of cancer treatment", filed June 16, 2009), which claims U.S. Provisional Patent Application Serial No. 61 Priority of / 061,968 (filed June 16, 2008). The contents of these patent applications are incorporated in this specification by reference data in their entirety. [0003] technical field of invention [0004] The present invention relates to the field of cancer vaccines. In particular, the application relates to a sugar-based vaccine containing the B-cell epitope GloboH complexed with the immunogenic carrier DT-CRM197. More specifically, the present invention relates to anti-cancer GloboH-DT vaccines co-administered with novel glycolipid adjuvants such as C34. Background of the invention [0005] To design therapies against ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/00A61K39/385
CPCA61K39/0011A61K39/385A61K39/39A61K2039/55511A61K2039/6081A61K2039/627C12N15/1137C12N2310/14A61K39/02A61K39/095A61K39/395
Inventor 翁启惠吴宗益陈铃津游正博
Owner ACAD SINIC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products